Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.62 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23801504 | 1.00 | IDO1 (0.65) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL29636319 | 0.88 | IDO1 (0.66) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL23801484 | 0.84 | IDO1 (0.75) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL23801461 | 0.83 | IDO1 (0.54) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL19900045 | 0.83 | IDO1 (0.54) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL19899835 | 0.83 | IDO1 (0.84) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL23801439 | 0.82 | IDO1 (0.69) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL21187109 | 0.82 | IDO1 (0.76) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL20916344 | 0.82 | IDO1 (0.76) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 | |
| SCHEMBL20905247 | 0.82 | IDO1 (0.76) | IDO1CYP2C9CYP2C8CHRNA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2152/4885CYP2C8 709/4885 |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2152/4885CYP2C8 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.